ROCO
4107
Market cap284mUSD
Nov 12, Last price
128.50TWD
Name
Bioteque Corp
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Bioteque Corporation manufactures and sells medical devices in Asia, South America, North America, and internationally. The company provides medical disposables for use in hemodialysis access, endovascular treatment, and other fields. It also offers dialysis products, including hemodialysis bloodlines, A.V.F. needles, and hemodialysis cathers; interventional radiology products, such as pigtail drainage catheter sets, introducer sets, connecting tubes, drainage bags, and radiopaque dilators; urology products comprising ureteral stent sets and urine collection bags; and IV administration products, such as PVC IV infusion bags, PVC bags, and twist-off ports. In addition, the company provides respiratory care products, such as closed suction catheters and endotracheal tubes; vascular access products comprising angiographic catheters, PTA balloon dilatation catheters, sheath introducers, guidewires, high pressure connecting tubes, PTCA balloon dilatation catheter-rapid exchange products, manifolds, and Y connectors; and medical components, including dialyzer connectors and caps, recirculating connectors with cap, rotating luer lock connectors, pump and T connectors, injection sites, female luers, luer lock and chamber caps, drip chambers, filters, clamps, pressure pillows, safeline HDF components, chamber assembly, and transducer protectors, as well as medical masks. Bioteque Corporation was incorporated in 1991 and is headquartered in Taipei, Taiwan.
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||